-
Complement factor C3 inhibitor
POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation. POT-4 can be used for age-related macular degeneration research - OVA 55-62 is a fragmented peptide of OVA (ovalbumin) antigen and can bind to the mouse MHC class I molecule, H2-Kb.
-
CKLF1/CCL17 inhibitor
CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4, and inhibits chemotaxis induced by both CKLF1 and CCL17. CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4. -
FKBP substrate
Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a substrate of FK-506 binding protein (FKBP). -
Porustobart is a monoclonal antibody specifically targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). This antibody is designed for use in research studies to investigate the modulation of immune checkpoints, which are crucial for understanding immune system behavior in cancer and other diseases. Porustobart can be utilized in various experimental settings, including flow cytometry, Western blotting, and immunoprecipitation, making it a valuable tool for researchers focusing on immunology and oncology.
-
Anti-CTLA-4/CD152 Antibody (BN13) is a chimeric mouse IgG2a, κ antibody designed to target human CTLA-4/CD152. For isotype control, it is recommended to use Mouse IgG2a kappa, Isotype Control, ensuring specificity and consistency in antibody performance.
-
Bavunalimab is a bispecific monoclonal antibody targeting CTLA-4 and LAG-3, designed for the dual inhibition of these immune checkpoint inhibitors. This humanized antibody promotes T-cell activation, demonstrated in NSG mouse models, making it a valuable tool for investigating immune responses in oncology research. Bavunalimab is specifically developed for studies focusing on the modulation of immune checkpoints in cancer therapy.
-
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody designed to specifically target and inhibit CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4). By antagonizing the inhibitory checkpoints mediated by CTLA-4 signaling, Zalifrelimab enhances immune cell activation, potentially amplifying antitumor immune responses. This antibody is utilized in research focused on immunotherapy and the modulation of immune checkpoints in oncology.
-
Nurulimab (BCD-145) is a human monoclonal antibody that targets cytotoxic T lymphocyte antigen-4 (CTLA-4). This antibody is specifically designed for use in melanoma research, where it can help investigate the role of CTLA-4 in tumor immunity and potential therapeutic interventions.
-
Tremelimumab (Ticilimumab) is a fully human monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research.
-
Encelimab is a monoclonal antibody targeting LAG-3 (Lymphocyte-activation gene 3). By inhibiting the interaction between LAG-3 and MHC class II molecules, Encelimab promotes T-cell activation and enhances immune responses. Studies have demonstrated that Encelimab, both as a monotherapy and in conjunction with an anti-PD-1 antibody, effectively reduces tumor volume in a lymphoma mouse model using A20 cell xenografts. This antibody is pivotal for research focused on immunotherapy and cancer immunology, particularly in understanding and manipulating T-cell responses in oncological models.
-
The Anti-CTLA-4/CD152 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CTLA-4 (CD152). This antibody comprises a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 145 kDa. For experimental controls, the recommended isotype control is Human IgG1 kappa. This antibody is essential for research focusing on immune checkpoint regulation and cancer immunotherapy.
-
Firastotug is an IgG1κ monoclonal antibody specifically designed to target CTLA-4, a critical immune checkpoint protein associated with cytotoxic T lymphocytes. CTLA-4 plays a pivotal role in regulating immune responses, making it a significant target in the study of autoimmunity and oncology. This antibody is instrumental for researchers focusing on the modulation of immune checkpoints to understand disease mechanisms and develop therapeutic strategies.
-
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody designed to simultaneously target PD-1 and CTLA-4. By inhibiting these checkpoint pathways, Cadonilimab effectively alleviates immunosuppression and reverses T cell exhaustion specific to tumor environments. This antibody notably reduces Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Cadonilimab is applicable in research focused on metastatic cervical cancer and other malignancies, including gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, and non-small cell lung cancer (NSCLC), providing a valuable tool for investigations into immune checkpoint blockade and cancer immunotherapy.
-
Favezelimab (MK-4280) is a humanized monoclonal antibody targeting LAG-3, designed to inhibit the binding of LAG-3 to MHC class II molecules. This interaction blockade enhances T-cell function and may potentiate an anti-tumor immune response. Favezelimab is primarily investigated for its therapeutic potential in colorectal cancer research, particularly in combination with the PD-L1 inhibitor Pembrolizumab, to synergistically enhance immune-mediated tumor suppression.
-
Evalstotug is a human IgG1 κ monoclonal antibody targeting CTLA-4 (Cytotoxic T-Lymphocyte-Associated protein 4). For accurate experimental control, it is recommended to use Human IgG1 kappa isotype control.
-
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART) designed to simultaneously inhibit the activity of PD-1 and CTLA-4 immune checkpoints. By blocking these pathways, Lorigerlimab enhances T-cell mediated immune responses, which are critical in the control and elimination of tumors. This antibody is particularly relevant for studies focused on metastatic castration-resistant prostate cancer (mCRPC), providing a valuable tool for research in immune checkpoint blockade therapies and their role in cancer immunology.
-
Fianlimab (REGN3767) is a human monoclonal antibody designed to specifically bind to the lymphocyte-activation gene 3 (LAG-3) immune checkpoint receptor expressed on T cells. This interaction inhibits the LAG-3 pathway, thereby enhancing T cell function and exhibiting potent anti-tumor activity. Fianlimab is utilized in oncological research to investigate immune checkpoint blockade as a strategy for cancer immunotherapy.
-
Tuparstobart (Incagn-02385) is an IgG1κ monoclonal antibody designed to specifically target LAG-3, an immune checkpoint receptor. LAG-3 is predominantly expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. This antibody is engineered to bind to LAG-3, thereby modulating immune responses, which may be critical in the research of immune regulation and potential therapeutic applications in immune-related disorders.
-
Relatlimab (BMS-986016) is a human monoclonal antibody targeting LAG-3, developed through the immunization of transgenic mice engineered to express human immunoglobulin miniloci, using recombinant LAG-3 protein. This antibody effectively inhibits the interaction between LAG-3 and MHC II with an IC50 of 0.67 nM, and between LAG-3 and FGL1 with an IC50 of 0.019 nM. It is primarily utilized in cancer research, providing a valuable tool for investigating the role of LAG-3 in tumor immune evasion and potential therapeutic interventions.
-
Erfonrilimab (KN-046) is a bifunctional monoclonal antibody designed to simultaneously inhibit both PD-L1 and CTLA-4, two critical immune checkpoint proteins. This dual inhibition mechanism enhances the immune system's ability to recognize and destroy cancer cells, making it a promising therapeutic agent in oncology research. Erfonrilimab is specifically engineered for use in investigating the efficacy of combined checkpoint blockade in various cancer models.
-
Miptenalimab (BI-754111) is a monoclonal antibody targeting human LAG-3 with a dissociation constant (K_D) of 88.6 nM. This antibody effectively inhibits the interaction between LAG-3 and its physiological ligand MHC class II, highlighting its potential utility in modulating immune responses in oncological and immunological research.
-
Ipilimumab is a fully human monoclonal antibody of the IgG1κ isotype designed to inhibit the cytotoxic T lymphocyte antigen 4 (CTLA-4) receptor on T cells. This antibody is utilized in research focused on unresectable or metastatic melanoma (MM), serving as a critical tool in investigating the modulation of immune checkpoints in cancer therapy.
-
Negalstobart is a human IgG4 κ monoclonal antibody targeting LAG-3. For control experiments, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.
-
neurotrophic agent
Leteprinim, also known as AIT-082 and SPI-205, is a neurotrophic agent potentially for the treatment of Alzheimer's disease, and spinal cord injury.
Immunology & Inflammation
Catalog No.
Product Name
Application
Product Information
Citations
